CareDx Price to Book Ratio 2013-2024 | CDNA
Historical price to book ratio values for CareDx (CDNA) over the last 10 years. The current price to book ratio for CareDx as of May 02, 2025 is 2.21.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| CareDx Price/Book Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | Book Value per Share | Price to Book Ratio |
| 2025-05-02 | 15.00 | 2.17 | |
| 2024-12-31 | 21.41 | $6.91 | 3.10 |
| 2024-09-30 | 31.23 | $5.15 | 6.07 |
| 2024-06-30 | 15.53 | $5.03 | 3.09 |
| 2024-03-31 | 10.59 | $4.95 | 2.14 |
| 2023-12-31 | 12.00 | $5.07 | 2.36 |
| 2023-09-30 | 7.00 | $7.28 | 0.96 |
| 2023-06-30 | 8.50 | $7.50 | 1.13 |
| 2023-03-31 | 9.14 | $7.83 | 1.17 |
| 2022-12-31 | 11.41 | $8.05 | 1.42 |
| 2022-09-30 | 17.02 | $8.16 | 2.09 |
| 2022-06-30 | 21.48 | $8.32 | 2.58 |
| 2022-03-31 | 36.99 | $8.62 | 4.29 |
| 2021-12-31 | 45.48 | $8.80 | 5.17 |
| 2021-09-30 | 63.37 | $8.95 | 7.08 |
| 2021-06-30 | 91.52 | $9.13 | 10.02 |
| 2021-03-31 | 68.09 | $9.08 | 7.50 |
| 2020-12-31 | 72.45 | $5.62 | 12.90 |
| 2020-09-30 | 37.94 | $5.47 | 6.94 |
| 2020-06-30 | 35.43 | $5.34 | 6.64 |
| 2020-03-31 | 21.83 | $2.36 | 9.26 |
| 2019-12-31 | 21.57 | $2.33 | 9.26 |
| 2019-09-30 | 22.61 | $2.30 | 9.83 |
| 2019-06-30 | 35.99 | $2.20 | 16.34 |
| 2019-03-31 | 31.52 | $2.28 | 13.82 |
| 2018-12-31 | 25.14 | $2.32 | 10.85 |
| 2018-09-30 | 28.85 | $1.14 | 25.21 |
| 2018-06-30 | 12.24 | $0.80 | 15.21 |
| 2018-03-31 | 7.97 | $0.95 | 8.41 |
| 2017-12-31 | 7.34 | $-0.21 | -35.53 |
| 2017-09-30 | 3.70 | $-0.01 | -474.36 |
| 2017-06-30 | 1.11 | $0.56 | 1.98 |
| 2017-03-31 | 1.40 | $0.70 | 2.01 |
| 2016-12-31 | 2.70 | $0.93 | 2.91 |
| 2016-09-30 | 3.55 | $1.73 | 2.05 |
| 2016-06-30 | 4.31 | $1.72 | 2.51 |
| 2016-03-31 | 4.96 | $1.71 | 2.90 |
| 2015-12-31 | 6.40 | $2.48 | 2.58 |
| 2015-09-30 | 4.17 | $2.85 | 1.46 |
| 2015-06-30 | 6.50 | $3.11 | 2.09 |
| 2015-03-31 | 5.55 | $3.34 | 1.66 |
| 2014-12-31 | 7.25 | $3.50 | 2.07 |
| 2014-09-30 | 7.00 | $3.48 | 2.01 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $0.839B | $0.334B |
| CareDx, Inc. is a commercial stage company. It develops, markets, and delivers a diagnostic surveillance solution for heart transplant recipients. The Company provides AlloMap, a noninvasive blood test used to aid in the identification of heart transplant recipients. It is also pursuing other areas of transplant surveillance, such as the use of cell-free DNA (cfDNA) as a biomarker for rejection. CareDx, Inc. is based in Brisbane, California. | |||